

Company Fact Sheet

Headquarters:

RefleXion Medical
25841 Industrial Blvd. Suite 275
Hayward, CA 94545
USA
+1 650.239.9070

Number of Employees:

100+

RefleXion Medical:

A privately-held biotargeting company founded in 2009 by Sam Mazin, Ph.D. and Akshay Nanduri to create a new radiation treatment modality through biological guidance for the treatment of localized and metastatic cancer.

RefleXion Technology:

RefleXion is developing a biology-guided radiotherapy (BgRT)* system that is the first to utilize the cancer itself to guide radiation delivery, even in tumors that are moving. The technology uses positron emission tomography (PET) in a novel way to guide personalized radiotherapy. RefleXion's platform enables a leap forward in the ongoing goal of conventional radiotherapy to manage motion, reduce tumor margins and diminish radiation toxicity, making it feasible to treat multiple tumors in the same session.

PET and Radiotherapy:

RefleXion's technology combines PET imaging with stereotactic radiotherapy for superior localization and tracking at the time of treatment delivery. By using the tumor's own emissions to guide radiation delivery, treatment margins and the radiation dose to healthy tissue may be significantly reduced. This novel approach represents a significant advance for patients by leveraging a proven modality for visualizing cancer with one of the most effective ways to treat cancer.

Funding & Investors:

RefleXion raised over \$100M in its Series C round of funding and is backed by premier investment firms TPG Growth/The Rise Fund, China-focused healthcare investment firm GT Healthcare Capital Partners, KCK Group, Sofinnova Partners, T. Rowe Price Associates, Inc., Venrock, Pfizer Venture Investments, and Johnson & Johnson Innovation, JJDC Inc. The company received grant funding from the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program.

Media Resources:

Todd Powell, president, CEO
Sam Mazin, Ph.D., founder, CTO
Akshay Nanduri, founder, vp, strategy and business development
Judy Bartlett-Roberto, vp, marketing
David Larkin, vp, research and development

*The RefleXion System requires 510(K) clearance and is not yet commercially available in the US.